The Latest Cardiac and Vascular News
INDIANAPOLIS, May 1, 2018 /PRNewswire/ — Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to […]
REDWOOD CITY, Calif., April 30, 2018 – Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next generation Pantheris® Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing […]
DUBLIN – April 23, 2018 – Medtronic plc (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon (DCB) to treat long superficial femoral artery (SFA) lesions up to 360mm […]
San Clemente, Calif., March 12, 2018 /PRNewswire/ — Reflow Medical Inc., a developer of innovative medical devices to combat cardiovascular disease, announced that the first patients have been enrolled in a prospective, multi-center, non-randomized study intended to evaluate the ability […]
SALT LAKE CITY–(BUSINESS WIRE)– XableCath, Inc., innovators of products designed to aid in the treatment of peripheral artery disease (PAD), announced that it has been granted a second U.S. Patent, No. 9,826,995, covering its XableCath™ catheter. The patent specifically describes […]
ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ — Abbott (NYSE: ABT) and Surmodics (NASDAQ: SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics’ SurVeil® drug-coated balloon to treat the superficial femoral […]
SUNNYVALE, Calif.–(BUSINESS WIRE)– PQ Bypass, a clinical-stage medical technology company that has developed the DETOUR procedure, a novel treatment for long (>15 cm) superficial femoral artery (SFA) blockages, announced enrollment of the first patients in the pivotal DETOUR II Trial in […]
REDWOOD CITY, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval for its next generation Pantheris Lumivascular atherectomy system, the first-ever […]
SUNNYVALE, Calif.–(BUSINESS WIRE)–PQ Bypass, Inc., today announced it has received conditional approval of its investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate the pivotal DETOUR II clinical trial. As the first-ever pivotal trial for […]
RARITAN, N.J., Dec. 11, 2017 /PRNewswire/ — Janssen Research & Development today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new XARELTO® (rivaroxaban) vascular indications: reducing the risk of major cardiovascular […]
